Accumulating evidence has demonstrated that aberrant expression of G3BP2 contributes to cancer initiation and progression, such as high expression of G3BP2 increasing cell stemness, metastasis and chemoresistance in breast cancer [11–13], upregulation of G3BP2 promoting cell growth and survival in prostate cancer [14], and bladder cancer [15]. This evidence concerns the gene G3BP2 and urinary bladder carcinoma.